Ordinace chorob plicnich s.r.o.
- Address
- Palackeho 720/5, Nove Mesto, 110 00 Prague, Czechia
Ordinace chorob plicnich s.r.o. - Pulmonary Disease Research Center
Ordinace chorob plicnich s.r.o. is a specialized pulmonary research center with extensive expertise in chronic obstructive pulmonary disease (COPD) clinical trials. The center focuses on evaluating novel therapeutic approaches and combination therapies aimed at improving lung function, reducing exacerbations, and enhancing quality of life for patients with moderate to severe COPD.
- Advanced triple therapy combinations (ICS/LABA/LAMA) and fixed-dose combination studies
- Novel add-on therapies for COPD exacerbation prevention
- Cardiopulmonary outcomes and biological therapy investigations
- Chronic bronchitis and severe COPD management strategies
The research center demonstrates particular strength in evaluating long-term efficacy and safety profiles of respiratory medications, with multiple 52-week treatment studies. Their clinical trial portfolio includes investigations of metered-dose inhalers, dry powder inhalers, and innovative biologics such as tezepelumab, reflecting their commitment to advancing both conventional and cutting-edge treatment modalities for chronic obstructive pulmonary disease and related respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ordinace chorob plicnich s.r.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jul 2023 | Jul 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 2 | Unknown | 2022-04-22 | 2024-07-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.